Probiotic Composition for Atopic Dermatitis Without Steroid Adverse Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atopic dermatitis, such as topical corticosteroids and calcineurin inhibitors, are effective but pose significant adverse effects, and there is a need for safer and more effective long-term alternatives.
Innovation Solution
A probiotic composition comprising Bifidobacterium animalis subs. lactis, Bifidobacterium longum, and Lactobacillus casei is administered to modify the intestinal microbiota, improving the SCORAD index and reducing the need for corticosteroid use in patients with atopic dermatitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical corticosteroids and calcineurin inhibitors are used to treat atopic dermatitis, then the disease symptoms are effectively controlled, but significant adverse effects occur
Solution Approach 1:
The patent introduces probiotics as an intermediary substance that modifies the intestinal microbiota to indirectly treat atopic dermatitis. Instead of directly applying corticosteroids to the skin, the treatment uses probiotics taken orally to alter gut flora composition, which then exerts a systemic effect on the immune system and skin condition, thereby avoiding direct skin exposure to harmful steroids.
Solution Approach 2:
The patent replaces the mechanical/chemical system of topical corticosteroid application with a biological system involving probiotics and microbiota modification. The treatment mechanism shifts from direct anti-inflammatory chemical action on skin to biological modulation through gut-skin axis, substituting harmful chemical substances with beneficial live microorganisms.
2Reliability
If probiotic composition is administered to modify intestinal microbiota, then the SCORAD index improves significantly and corticosteroid use is reduced, but the treatment mechanism involves complex biological interactions
Solution Approach 1:
The probiotic composition performs self-service by utilizing the patient's own intestinal environment to amplify therapeutic effects. The administered probiotics colonize the gut and actively modify the existing microbiota composition, creating a self-sustaining therapeutic mechanism that continues to benefit the patient even after treatment cessation, reducing the need for ongoing corticosteroid intervention.
Data Source
AI summary
The present invention is intended for the use of a probiotic composition comprising Bifidobacterium animalis subs. lactis (B. lactis), Bifidobacterium longum and Lactobacillus casei, particularly the strains B. lactis CECT 8145, B. longum CECT 7347 and/or L. casei CECT 9104, in the treatment and/or prevention of atopic dermatitis.